顺铂联合吉西他滨与顺铂联合长春瑞宾治疗晚期非小细胞肺癌的疗效和不良反应比较被引量：28

Comparison of Cisplatin Combined with Gemcitabine Versus Cisplatin Combined with Vinorelbine Regimen for Treatment of Patients with Advanced Non-Small Cell Lung Cancer

暂未订购

导出

摘要背景与目的:化疗是治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的主要方法,该方法可适当延长患者生存期、减轻临床症状、改善生活质量。本研究目的在于观察、比较顺铂联合吉西他滨与顺铂联合长春瑞宾治疗晚期NSCLC的初步疗效及患者的耐受性。方法:晚期NSCLC患者64例,分别接受顺铂+吉西他滨(PG)方案或顺铂+长春瑞宾(PN)方案治疗,PG组31例,PN组33例。两组患者特征具有可比性(P>0.05)。结果:两组均有31例可以评价疗效。PG组CR1例,PR9例,NC17例,PD4例,有效率32.3%(95%可信区间犤CI犦:16.3%～48.7%);PN组无CR,PR9例,NC17例,PD5例,有效率29.03%(95%可信区间犤CI犦:13.1%～44.9%)。两组有效率差异无统计学意义(P=0.526,χ2检验)。PG组中位生存期12个月(95%CI:10～14个月);PN组中位生存期11个月(95%CI:10～12个月),两组生存期比较差异无统计学意义(P=0.5799,Log-rank检验)。不良反应主要为骨髓抑制。PN组白细胞减少明显(P=0.009),而PG组血小板减少明显(P=0.01)。结论:PG方案和PN方案治疗晚期NSCLC均有一定的疗效,两方案疗效相似。不良反应方面PG组以血小板减少为主,PN组以白细胞减少为主;且有神经毒的表现。 BACKGROUND ＆OBJECTIVE: In most instances, advanced non small cell lung cancer (NSCLC) is treated with primary chemotherapy. Many chemotherapy regimens can palliate cancer related symptoms and modestly improve survival and quality of life. This clinical trial was designed to compare the efficacy and toxicity of two regimens: PG regimen [cisplatin and gemcitabine] versus PN regimen [cisplatin and vinorelbine]. METHODS: A total of 64 patients were enrolled in this study, 31 patients received PG regimen and 33 patients received PN regimen. Patients in both groups were well matched with baseline disease characteristics (P >0 05). RESULTS: In PG group, the response rate was 32 3％〓[10/31, 95％〓confidence interval (CI):16 3％－48 7％][1 complete response (CR), 9 partial response (PR), 17 no change (NC), 4 progressive disease (PD)]; whereas in group PN, the response rate was 29 03％〓(9/31，95％〓CI:13 1％－44 9％) (0CR, 9PR, 17NC, 5PD). The difference of response rates between two groups was not statistically significant (P=0 526, Chi square test). The median survival were 12 months for group PG (95％CI:10 14 months) and 11 months for group PN (95％〓CI:10 12months). The difference of median survival between two groups was not statistically significant(P=0 5799，log rang test).The major toxicity was myelosuppression. Leucopenia was more pronounced in group PN (P=0 009), Thrombocytopenia was more pronounced in group PG(P=0 01).CONCLUSION:PG and PN are two effective regimens for the patients with advanced NSCLC;the major toxicity was myelosuppression.Leucopenia was pronounced in group PN. Thrombocytopenia was pronounced in group PG. Neurotoxicity was observed in group PN.

作者滕小玉周宁宁苏义顺周中梅刘冬耕何友兼

机构地区中山大学肿瘤防治中心内科

出处《癌症》 SCIE CAS CSCD 北大核心 2003年第4期404-406,共3页 Chinese Journal of Cancer

关键词肺肿瘤顺铂吉西他滨长春瑞宾药物联合疗法 Non small cell lung cancer (NSCLC) Chemotherapy Cisplatin Gemcitabine Vinorelbine

分类号 R734.2 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献4

1[1]Robert J,Everett E,Kenneth R. Cancer of the Lung:Non- Small Cell Lung Cancer. Vincent T. DeVita, Samuel Hellman, Steven A. Rosenberg,Cancer:Principles ＆ Practice of Oncology,6th Edition Published by Lippincott Williams ＆ Wilkins,Copyright 2001. Chapter 31.2:950.
2[2]Steward WP. Combination studies with gemcitabine in the treatment of non small cell lung cancer [J]. Br J Cancer,1998,78:15- 19.
3[3]Wozniak AJ,Crowley JJ,Balcerzak SP,et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of dvanced non- small- cell lung cancer:a Southwest Oncology Group study [J]. J Clin Oncol,1998,16(7):2459- 2465.
4[4]Comella P,Frasci G,Panza N,et al. Randomized trial comparing cisplatin,gemcitabine,and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non small cell lung cancer:interim analysis of a phase Ⅲ trial of the Southern Italy Cooperative Oncology Group [J]. J Clin Oncol,2000,18(7):1451- 1457.